A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA
Mad in America
AUGUST 14, 2024
By 2019, two Phase 3 trials of aducanumab were terminated early because the drug wasn’t improving outcomes and was clearly causing harm (a large percentage of the participants were experiencing brain bleeding known as ARIA). Perhaps because MDMA-assisted therapy isn’t a simple drug to be prescribed by psychiatrists.
127 
Let's personalize your content